Mediating Role of Chiro-inositol Metabolites on the Effects of HLA-DR-expressing CD14+ Monocytes in Inflammatory Bowel Disease

doi:10.21203/rs.3.rs-4188311/v1

Download PDF

Research Article

Mediating Role of Chiro-inositol Metabolites on the Effects of HLA-DR-expressing CD14+ Monocytes in Inflammatory Bowel Disease

https://doi.org/10.21203/rs.3.rs-4188311/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 17 Jun, 2024

Read the published version in BMC Gastroenterology →

You are reading this latest preprint version

Background

Inflammatory bowel disease (IBD), a chronic inflammatory condition, is caused by several factors involving aberrant immune responses. Genetic factors are crucial in the occurrence of IBD. Mendelian randomization (MR) can offer a new perspective in understanding the genetic background of IBD.

Methods

The two-sample MR approach was used to estimate the causal relationship of immune cells to IBD. Single nucleotide polymorphisms (SNPs) were considered instrumental variables (IVs). We analyzed the relationship between 731 immunophenotypes, 1,400 metabolite phenotypes, and IBD.

Results

We identified the causal effects of HLA-DR-expressing CD14 + monocytes on IBD through MR analysis. The phenotype of "HLA-DR expression on CD14 + monocytes" showed the strongest association among the selected 48 immune phenotypes. Chiro-inositol metabolites mediate the effect of CD14 + monocytes expressing HLA-DR on IBD. An increase in Chiro-inositol metabolites was associated with a reduced risk of IBD occurrence, accounting for 4.97%.

Conclusion

Our findings reveal a new pathway by which HLA-DR-expressing CD14 + monocytes indirectly reduce the risk of IBD occurrence by increasing the levels of Chiro-inositol metabolites, providing a new perspective on the immunoregulatory mechanisms underlying IBD. It lays a theoretical foundation for developing new therapeutic targets.

Inflammatory Bowel Disease

Immunity

Metabolite

Causal Inference

Mendelian Randomization Analysis

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory condition targeting the colon and small intestine[1, 2]. IBD poses challenges to the patient’s well-being and healthcare systems globally and is characterized by a spectrum of symptoms, such as abdominal pain, diarrhea, and weight loss[3]. The incidence of IBD is on the rise worldwide, with a notable onset in young individuals, inflicting a substantial proportion diagnosed before the age of 18 years[4, 5]. This trend, along with the increased risk observed among first-degree relatives of patients with IBD, highlights the remarkable genetic component of the disease and the need for a deeper understanding of its hereditary patterns and environmental triggers[6–8]. Its complex etiology, involving an interplay of genetic, environmental, and immune factors, underscores the necessity for advanced research to understand its pathogenesis and improve therapeutic outcomes[9].

At the core of IBD's pathogenesis is immune system dysregulation, manifesting through abnormal responses of T cells, B cells, mast cells, activated neutrophils, and macrophages[10], contributing to the chronic inflammation in IBD. Therefore, research into the genetic and molecular mechanisms underpinning immune cell functions and their interaction in the context of IBD is necessary[11–14]. Understanding these interactions is crucial to identify new therapeutic targets and elucidate the complex network of factors contributing to the development of IBD. Genome-wide association studies (GWASs) have unveiled over 200 genomic loci linked to IBD and serve as a foundation for genetic inquiries[15]. These discoveries have facilitated exploration into the association of IBD with its causative factors[16–18]. The research focus has recently shifted towards the role of immune cells in the development of IBD, highlighting their dual role in initiating and mitigating intestinal inflammation[19]. Despite these insights enhancing our knowledge of IBD's pathophysiology and inflammatory regulation, the quest for definitive causal connections at the population level remains challenging.

Mendelian randomization (MR), leveraging genetic variants from GWASs as instrumental variables (IVs), is pivotal in bridging the gap between genetic predispositions and IBD by establishing causal links between genetic factors and this disease[20]. This approach is grounded in the principle that genetic variations are randomly distributed, allowing for exploring the genetic architecture of IBD and the role of immune cells. This offers novel insights into its pathogenesis and potential interventions, circumventing confounding factors typical in observational studies[21, 22]. MR offers unique advantages compared to time-consuming and resource-intensive randomized controlled trials (RCTs). In this study, genetic variants from large GWASs were collected and the causal relationship between 731 immunophenotypes, 1400 metabolite phenotypes, and IBD was analyzed. We investigated the effects of immune cells on IBD and the mediating role of metabolites through MR analysis. Our findings elucidate the complex interplay between immune cells, metabolites, and IBD, offering novel insights into identifying potential diagnostic biomarkers and therapeutic targets.

Study Design

We conducted a two-sample MR analysis to determine the causal relationship of immune cells with IBD. Single nucleotide polymorphisms (SNPs) were considered IVs to define these relationships. MR analysis is based on the following three assumptions: (1) genetic variations used as IVs are associated with immune traits; (2) IVs are independent of confounding factors; (3) IVs affect IBD only through their effect on immune traits and not through other pathways[23].

Data sources

Data on IBD utilized were sourced from the FinnGen GWAS (https://r10.finngen.fi/, including 9,083 cases of IBD and 403,098 controls). The data included IBD cases evaluated through imaging, endoscopy, and pathological assessments to ensure compliance with clinical diagnostic criteria[24].

We analyzed 731 immunophenotypes derived from 3,757 European individuals, including absolute cell counts, median fluorescence intensities, morphological parameters, and relative cell counts, spanning a pectrum of immune cells at various stages of maturation. Supplementary Table 1 presents the detailed immunophenotypes. We used 22 million SNPs, adjusted for factors such as sex and age, ensuring a robust analysis of genetic influences on these immune traits without cohort overlap, using data imputed from the Sardinian genetic reference[25].

Metabolites analyzed were sourced from the Canadian Longitudinal Study on Aging (CLSA) cohort, encompassing a comprehensive array of 1,091 metabolite phenotypes and 309 metabolite phenotype ratios from 8,299 participants[26]. Supplementary Table 2 presents the detailed metabolite phenotypes. This rich dataset provided a solid foundation for investigating the metabolic factors potentially affecting IBD pathogenesis.

IV Selection

We referred to the latest research findings and rigorously selected IVs suitable for MR analysis to ensure the accuracy and reliability of our evaluation[27]. SNPs were required to meet a genome-wide significance level (p < 5×10^− 8). A clumping algorithm was utilized to avoid linkage disequilibrium effects (r² = 0.001 and kb = 10,000). SNPs were selected based on their specific effect on immune cells and metabolites without direct effects on IBD. This ensured a sufficient F-statistic value to confirm the strength of the genetic instruments (F-statistics > 10)[28, 29]. These steps ensured the construction of a reliable framework for examining the genetic connections between immune cells, metabolites, and IBD to yield precise insights into the disease.

Statistical analysis

An MR analysis was performed using the TwoSampleMR software package (version 0.5.6) in the R software (version 4.3.2)[30]. In our study, the inverse variance weighted (IVW) method was the primary analytical tool to explore the causal relationships among 731 immunophenotypes, 1,400 metabolite phenotypes, and IBD. This approach, involving a weighted regression of SNP-specific Wald ratios, allows for the precise assessment of the causal effect of these variables on IBD. This highlights the foundational role of IVW in our investigation into the complex relationships within our dataset[31, 32]. MR Egger[33], weighted median[34], and weighted mode were used as supplementary analyses to test the robustness of the results. MR-Egger analysis assesses the directional pleiotropy, capturing an average effect of genetic variation's pleiotropy through its intercept. The weighted median approach is remarkable for its accuracy and resilience to pleiotropy. It reliably provides consistent estimates but a significant proportion of SNPs might not serve as valid IVs[35].

Primary Analysis

Figure 1 presents a diagrammatic overview of our analyses. We assessed the reciprocal causative relationships between immune cells and IBD through a two-sample bidirectional MR, termed the total effect in Fig. 1A.

We aimed to identify the immune cells with the most significant statistical association (smallest P-value) with IBD through cycling analysis of 731 immunophenotypes, focusing on their mediating effects. This approach allows for a targeted examination of the potential intermediaries between specific immune cell types and the pathogenesis of IBD.

Mediation analysis

We expanded our analysis with mediation to assess if metabolites mediate immune cell function in IBD, as shown in Fig. 1B[36]. This analysis differentiated between the direct effect of immune cells on IBD and that channeled through metabolites. We quantified the mediated percentage by dividing the mediated effect by the total effect, applying the delta method for the corresponding 95% confidence intervals[37].

Sensitivity Analysis

The Cochran's Q statistic and funnel plots were used to evaluate heterogeneity among SNPs [38, 39]. A leave-one-out analysis was conducted to ensure the robustness of the results and any single SNP's significant effect on the findings of MR analysis[40]. We explored the reciprocal effect of IBD on immune cell composition, utilizing the MR-PRESSO method for detecting outliers to mitigate bias from horizontal pleiotropy, thereby enhancing the credibility of our causal interpretations within this intricate relationship between the immune system and IBD[41].

Association of HLA-DR-expressing CD14 + Monocytes with IBD

Based on the IVW method, we investigated the causal effect of 731 immunophenotypes on IBD by a two-sample MR method. SNPs with a p-value < 5×10^− 8 were selected as IVs, while palindromic and ambiguous SNPs were excluded to ensure clarity and accuracy.

Our analysis using the IVW method identified 48 immunophenotypes exhibiting significant associations (p-value < 0.05) with IBD from 731 immunophenotypes (Supplementary Table 3). We selected the immunophenotype most likely to exhibit significant associations for subsequent mediation analysis, specifically "HLA-DR on CD14 + monocyte," demonstrating the smallest p-value (p = 3.86 × 10^− 6), indicating a strong potential association. The odds ratio was 0.911 (95% CI = 0.876–0.948).

IVW, MR-Egger, weighted median, and weighted mode were used to evaluate the causal relationships between HLA-DR-expressing CD14 + monocytes and IBD, as shown in Figs. 2 and 3. Evidence strongly supported a positive correlation between HLA-DR-expressing CD14 + monocytes and the incidence of IBD consistently across methodologies.

We conducted reverse MR analysis to verify the effect of the mediation effect due to reverse causation. The results indicated no association across methods, confirming that the mediation analysis was unaffected by reverse causation factors (Supplementary Table 4).

Identifying Mediator Metabolite Phenotypes

We performed a cyclical analysis between HLA-DR-expressing CD14 + monocytes and 1,400 metabolite phenotypes utilizing the IVW method and identified 51 metabolite statistically significant metabolites (P- value < 0.05), as shown in Supplemental Table 5.

We identified three metabolite phenotypes with significant associations (p- value < 0.05) that may function as mediators affecting the outcome among the 51 metabolite phenotypes known to be associated with IBD. These included "Chiro-inositol levels," "1-arachidonoyl-gpc (20:4n6) levels," and "Pregnenetriol sulfate levels."

From preliminary mediation analysis, the mediation effects of "1-arachidonoyl-gpc (20:4n6) levels" and "Pregnenetriol sulfate levels" for HLA-DR-expressing CD14 + monocytes on IBD were contrary to the direct effects. The mediation action of these two metabolites counteracted each other in the context of HLA-DR-expressing CD14 + monocytes affecting IBD. We focused solely on "Chiro-inositol metabolites" for subsequent mediation analysis and excluded the others. Supplemental Figs. 1 and 2 are forest plots indicating the mediation effects of "1-arachidonoyl-gpc (20:4n6) levels" and "Pregnenetriol sulfate levels."

Association of HLA-DR-expressing CD14 + Monocytes with Chiro-inositol Metabolites

Genetically predicted HLA-DR-expressing CD14 + monocytes and Chiro-inositol metabolites were positively correlated based on the IVW, MR Egger, weighted median, and weighted mode methods. In the IVW method, the odds ratio (OR) was 1.05 (CI = 1.01–1.10); in MR-Egger analysis, it was 1.06 (CI = 0.98–1.15); in the weighted median method, the OR was 1.04 (CI = 0.98–1.11), and in the weighted mode methods, the OR was 1.04 (CI = 0.98–1.11). Further details are shown in Fig. 3.

Association of Chiro-inositol Metabolites with IBD

Similarly, employing the four methods, including IVW, a negative correlation between Chiro-inositol Metabolites and the risk of IBD was found (Fig. 3). Specifically, in the IVW method, the OR was 0.92 (CI = 0.84–0.99); in the MR-Egger analysis, the OR was 0.81 (CI = 0.63–1.04); in the weighted median, the OR was 0.92 (CI = 0.83–1.02), and in the weighted mode, the OR was 0.92 (CI = 0.77–1.09).

Levels of Association between HLA-DR-expressing CD14 + Monocytes and IBD Mediated by Chiro-inositol Metabolites

We analyzed the mediating role of Chiro-inositol Metabolites on the effect of HLA-DR-expressing CD14 + monocytes on IBD. An elevation in HLA-DR expression correspondingly increased Chiro-inositol metabolites, which, in turn, reduced the risk of IBD development. As shown in Fig. 4, mediation effect calculation suggested that Chiro-inositol metabolites reduced the risk of IBD development posed by HLA-DR-expressing CD14 + monocytes, accounting for 4.97% of the effect (level mediated: 4.97%; 95%CI= -3.2–13.2%).

Our study, leveraging a vast array of publicly available genetic data, pioneers the application of MR analysis to assess the causal relationships between 731 immunophenotypes, 1,400 metabolite phenotypes, and IBD. To date, no comprehensive causal analysis has covered such an extensive range of immune phenotypes, metabolite phenotypes, and IBD. We identified the causal associations between 48 immunophenotypes and IBD, with "HLA-DR on CD14 + monocytes" significantly protective effects against IBD. From 1,400 metabolite phenotypes, we recognized the role of Chiro-inositol metabolites in mediating the protective effect of HLA-DR-expressing CD14 + monocytes against IBD at 4.97%. HLA-DR-expressing CD14 + monocytes reduced the risk of IBD onset, wherein Chiro-inositol Metabolites functioned indirectly.

Monocytes typically participate in immune responses and the regulation of inflammation[42]. HLA-DR molecules, belonging to the Major Histocompatibility Complex (MHC) class II molecules, are pivotal in antigen presentation and immune regulation[43]. Asmussen et al. indicated that low HLA-DR expression in chronic inflammatory monocytes underscores the anti-inflammatory role of HLA-DR molecules[44]. We utilized the MR method to provide new genetic evidence for the causal relationship between HLA-DR-expressing CD14 + monocytes and IBD, confirming the role of HLA-DR-expressing CD14 + monocytes in IBD.

The mediating role of Chiro-inositol metabolites in the effect of HLA-DR-expressing CD14 + monocytes on IBD was determined. Chiro-inositol is crucial in intracellular signaling and glycolipid metabolism[45]. Supplementation with a mixture of β-glucans, inositol, and digestive enzymes enhances the quality of life for patients with IBD[46]. Our findings corroborate that Chiro-inositol can reduce the risk of IBD onset and mediate its effects through HLA-DR-expressing CD14 + monocytes.

We precisely identified specific immune cells and metabolites associated with the risk of IBD through MR analysis, revealing numerous novel potential pathways from various immune cells to IBD. HLA-DR-expressing CD14 + monocytes exert a protective effect against IBD. This finding resonates with previous results on the role of immune cells in IBD[47], providing new evidence for the involvement of this cell type in the immune regulation of IBD. Chiro-inositol, as a mediating factor, offers a new perspective on the immune regulatory mechanisms of IBD. The regulation of myo-inositol is more feasible compared to immune cells [48]. Although the specific mechanisms of the chiro-inositol metabolic pathway in IBD necessitate further investigation, our findings lay the theoretical groundwork for developing new therapeutic targets.

However, some limitations of our study warrant further consideration. First, although MR analysis can effectively reduce the effect of confounding factors, all potential confounders, especially unknown genetic variants that might influence the study outcomes, cannot be excluded. Second, although our study is based on data from large-scale GWASs, the samples were primarily from European populations, so the results cannot be generalized to populations of other ethnicities or geographic regions. The mediating role of Chiro-inositol metabolites between HLA-DR-expressing CD14 + monocytes and IBD is relatively small, suggesting the presence of other undiscovered mediating mechanisms.

Based on our findings, subsequent research should explore the mechanisms of HLA-DR-expressing CD14 + monocyte action in immune regulation, and preventing and treating IBD by modulating Chiro-inositol metabolites. Investigating other biological pathways related to Chiro-inositol metabolism can reveal new therapeutic targets. Ultimately, validating these findings across diverse populations and environmental factors can support the development of personalized treatment strategies.

In summary, we identified the protective effect of HLA-DR-expressing CD14 + monocytes against IBD, with a minor role of Chiro-inositol metabolites. However, most of the effects of HLA-DR-expressing CD14 + monocytes on IBD remain unclear. Further research is required to investigate other potential risk factors that may serve as mediators. More attention must be given to the effect of HLA-DR-expressing CD14 + monocytes on patients with IBD.

Ethics approval and consent to participate

Ethics approval was not applicable since the study is based on summary-level data. In all original studies, ethics approval and consent to participate was obtained.

Consent for publication

Not applicable.

Competing interests

The authors declare no potential competing interests.

Funding

This study received financial support from a research fund from the National Natural Science Foundation of China (82374454 and 82260938).

Availability of data and materials

The present study involves summary-level data that have been made publically available. Summary data from genome-wide association studies on inflammatory bowel disease are available at https://risteys.finregistry.fi/endpoints/K11_IBD_STRICT. We collected dataon immune cells and metabolites. Data on 731 immunophenotypes are available from https://gwas.mrcieu.ac.uk/. Detailed GWAS IDs are provided in Supplementary Table 1. Data on 1,400 metabolite phenotypes were obtained from https://www.ebi.ac.uk/gwas/. Detailed IDs are provided in Supplementary Table 2.

Authors’ contributions

LZ, PS, and XJY led the project, conceptualized the study, and were major contributors to writing the manuscript. WG, WL, and QL analyzed and interpreted the data. CL and CZ assisted in data collection and analysis. XY and XZ prepared the figures and tables. All authors (LZ, PS, WG, WL, QL, CL, CZ, XY, XZ, and XJY) drafted the manuscript and revised it critically for important intellectual content. All authors have given final approval for the version to be published.

Acknowledgments

We thank the people involved in database collation for providing public access to the data.

Leitner GC, Vogelsang H. Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World J Gastrointest Pharmacol Ther. 2016;7:5–20.
Kassam Z, Belga S, Roifman I, Hirota S, Jijon H, Kaplan GG, et al. Inflammatory bowel disease cause-specific mortality: a primer for clinicians. Inflamm Bowel Dis. 2014;20:2483–92.
Guan Q. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. J Immunol Res. 2019;2019:7247238.
Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–7.
Yu YR, Rodriguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26:349–55.
Torres J, Gomes C, Jensen CB, Agrawal M, Ribeiro-Mourão F, Jess T, et al. Risk Factors for Developing Inflammatory Bowel Disease Within and Across Families with a Family History of IBD. J Crohns Colitis. 2023;17:30–6.
Kim HJ, Shah SC, Hann HJ, Kazmi SZ, Kang T, Lee JH, et al. Familial Risk of Inflammatory Bowel Disease: A Population-Based Cohort Study in South Korea. Clin Gastroenterol Hepatol. 2021;19:2128–e213715.
Kevans D, Silverberg MS, Borowski K, Griffiths A, Xu W, Onay V, et al. IBD Genetic Risk Profile in Healthy First-Degree Relatives of Crohn’s Disease Patients. J Crohns Colitis. 2016;10:209–15.
Lee SH, Kwon JE, Cho M-L. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018;16:26–42.
Wei S-Y, Wu T-T, Huang J-Q, Kang Z-P, Wang M-X, Zhong Y-B, et al. Curcumin alleviates experimental colitis via a potential mechanism involving memory B cells and Bcl-6-Syk-BLNK signaling. World J Gastroenterol. 2022;28:5865–80.
Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol. 2019;20:970–9.
Hou Q, Huang J, Ayansola H, Masatoshi H, Zhang B. Intestinal Stem Cells and Immune Cell Relationships: Potential Therapeutic Targets for Inflammatory Bowel Diseases. Front Immunol. 2020;11:623691.
Verstockt B, Vetrano S, Salas A, Nayeri S, Duijvestein M, Vande Casteele N, et al. Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2022;19:351–66.
Mirsepasi-Lauridsen HC, Vallance BA, Krogfelt KA, Petersen AM. Escherichia coli Pathobionts Associated with Inflammatory Bowel Disease. Clin Microbiol Rev. 2019;32:e00060–18.
Turpin W, Goethel A, Bedrani L, Croitoru Mdcm K. Determinants of IBD Heritability: Genes, Bugs, and More. Inflamm Bowel Dis. 2018;24:1133–48.
Liu B, Ye D, Yang H, Song J, Sun X, Mao Y, et al. Two-Sample Mendelian Randomization Analysis Investigates Causal Associations Between Gut Microbial Genera and Inflammatory Bowel Disease, and Specificity Causal Associations in Ulcerative Colitis or Crohn’s Disease. Front Immunol. 2022;13:921546.
Zhuang Z, Li N, Wang J, Yang R, Wang W, Liu Z, et al. GWAS-associated bacteria and their metabolites appear to be causally related to the development of inflammatory bowel disease. Eur J Clin Nutr. 2022;76:1024–30.
Zhang Z-J, Qu H-L, Zhao N, Wang J, Wang X-Y, Hai R, et al. Assessment of Causal Direction Between Gut Microbiota and Inflammatory Bowel Disease: A Mendelian Randomization Analysis. Front Genet. 2021;12:631061.
Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329–42.
Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and Scope. Cold Spring Harb Perspect Med. 2022;12:a040501.
Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol. 2015;181:251–60.
Yarmolinsky J, Relton CL, Lophatananon A, Muir K, Menon U, Gentry-Maharaj A, et al. Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis. PLoS Med. 2019;16:e1002893.
Hartwig FP, Davies NM, Hemani G, Davey Smith G. Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int J Epidemiol. 2016;45:1717–26.
Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613:508–18.
Wang C, Zhu D, Zhang D, Zuo X, Yao L, Liu T, et al. Causal role of immune cells in schizophrenia: Mendelian randomization (MR) study. BMC Psychiatry. 2023;23:590.
Chen Y, Lu T, Pettersson-Kymmer U, Stewart ID, Butler-Laporte G, Nakanishi T, et al. Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases. Nat Genet. 2023;55:44–53.
Gagliano Taliun SA, Evans DM. Ten simple rules for conducting a mendelian randomization study. PLoS Comput Biol. 2021;17:e1009238.
Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int J Epidemiol. 2016;45:1961–74.
Wang B, Liu D, Song M, Wang W, Guo B, Wang Y. Immunoglobulin G N-glycan, inflammation and type 2 diabetes in East Asian and European populations: a Mendelian randomization study. Mol Med. 2022;28:114.
Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46:1734–9.
Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.
Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37:658–65.
Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32:377–89.
Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016;40:304–14.
Zhang Y, Liu Z, Choudhury T, Cornelis MC, Liu W. Habitual coffee intake and risk for nonalcoholic fatty liver disease: a two-sample Mendelian randomization study. Eur J Nutr. 2021;60:1761–7.
Carter AR, Sanderson E, Hammerton G, Richmond RC, Davey Smith G, Heron J, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol. 2021;36:465–78.
Leal SM. Genetics and Analysis of Quantitative Traits. Am J Hum Genet. 2001;68:548–9.
Tan J-S, Liu N-N, Guo T-T, Hu S, Hua L. Genetically predicted obesity and risk of deep vein thrombosis. Thromb Res. 2021;207:16–24.
Tan J-S, Ren J-M, Fan L, Wei Y, Hu S, Zhu S-S et al. Genetic Predisposition of Anti-Cytomegalovirus Immunoglobulin G Levels and the Risk of 9 Cardiovascular Diseases. Front Cell Infect Microbiol. 2022;12.
Cheng H, Garrick DJ, Fernando RL. Efficient strategies for leave-one-out cross validation for genomic best linear unbiased prediction. J Anim Sci Biotechnol. 2017;8:38.
Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50:693–8.
Linton L, Karlsson M, Grundström J, Hjalmarsson E, Lindberg A, Lindh E, et al. HLA-DR(hi) and CCR9 Define a Pro-Inflammatory Monocyte Subset in IBD. Clin Transl Gastroenterol. 2012;3:e29.
Mitsialis V, Wall S, Liu P, Ordovas-Montanes J, Parmet T, Vukovic M, et al. Single-Cell Analyses of Colon and Blood Reveal Distinct Immune Cell Signatures of Ulcerative Colitis and Crohn’s Disease. Gastroenterology. 2020;159:591–e60810.
Asmussen A, Busch H-J, Helbing T, Bemtgen X, Smolka C, Bode C, et al. Monocyte subset distribution and surface expression of HLA-DR and CD14 in patients after cardiopulmonary resuscitation. Sci Rep. 2021;11:12403.
Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013;95:1811–27.
Spagnuolo R, Cosco C, Mancina RM, Ruggiero G, Garieri P, Cosco V, et al. Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2017;21(2 Suppl):102–7.
Heresbach D, Alizadeh M, Reumaux D, Colombel JF, Delamaire M, Danze PM, et al. Are HLA-DR or TAP genes genetic markers of severity in ulcerative colitis? J Autoimmun. 1996;9:777–84.
Arefhosseini S, Roshanravan N, Tutunchi H, Rostami S, Khoshbaten M, Ebrahimi-Mameghani M. Myo-inositol supplementation improves cardiometabolic factors, anthropometric measures, and liver function in obese patients with non-alcoholic fatty liver disease. Front Nutr. 2023;10:1092544.

No competing interests reported.

Download PDF

Journal Publication

published 17 Jun, 2024

Read the published version in BMC Gastroenterology →

Editorial decision: Revision requested
19 Apr, 2024
Reviews received at journal
18 Apr, 2024
Reviews received at journal
18 Apr, 2024
Reviewers agreed at journal
10 Apr, 2024
Reviewers agreed at journal
08 Apr, 2024
Reviewers invited by journal
08 Apr, 2024
Editor invited by journal
08 Apr, 2024
Submission checks completed at journal
06 Apr, 2024
Editor assigned by journal
06 Apr, 2024
First submitted to journal
29 Mar, 2024

You are reading this latest preprint version

Mediating Role of Chiro-inositol Metabolites on the Effects of HLA-DR-expressing CD14+ Monocytes in Inflammatory Bowel Disease

Status:

Journal Publication

Version 1

Abstract

Background

Methods

Results

Conclusion

Figures

Introduction

Methods

Study Design

Data sources

IV Selection

Statistical analysis

Primary Analysis

Mediation analysis

Sensitivity Analysis

Results

Association of HLA-DR-expressing CD14 + Monocytes with IBD

Identifying Mediator Metabolite Phenotypes

Association of HLA-DR-expressing CD14 + Monocytes with Chiro-inositol Metabolites

Association of Chiro-inositol Metabolites with IBD

Levels of Association between HLA-DR-expressing CD14 + Monocytes and IBD Mediated by Chiro-inositol Metabolites

Discussion

Conclusion

Declarations

Ethics approval and consent to participate

Consent for publication

Competing interests

Funding

Availability of data and materials

Authors’ contributions

Acknowledgments

References

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 1